Compare SNFCA & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNFCA | GALT |
|---|---|---|
| Founded | 1965 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.1M | 232.3M |
| IPO Year | N/A | N/A |
| Metric | SNFCA | GALT |
|---|---|---|
| Price | $9.35 | $6.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 31.8K | ★ 465.8K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $340,876,482.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.19 | ★ N/A |
| Revenue Growth | ★ 3.25 | N/A |
| 52 Week Low | $7.32 | $0.73 |
| 52 Week High | $12.83 | $6.66 |
| Indicator | SNFCA | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 72.54 | 61.80 |
| Support Level | $8.52 | $5.10 |
| Resistance Level | $8.82 | $6.32 |
| Average True Range (ATR) | 0.26 | 0.56 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 100.00 | 93.06 |
Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.